Abba Hushi Avenue
About Check-CapCheck-Cap is a clinical stage medical diagnostics company leading the development of the first ingestible imaging capsule that utilizes low-dose X-rays for CRC screening.
The Check-Cap device requires no bowel preparation or invasive procedures, and is designed to detect clinically significant polyps with a high degree of sensitivity. Check-Cap's advanced technology has been proven in animals, and is designed to offer several advantages compared to current screening procedures.
Founded in early 2005, Check-Cap recruited a team of world-class experts in physics, software engineering, electronics, mechanics and physiology, who have been developing a multi-disciplinary imaging solution for imaging and screening of the colon. The system includes a capsule, a receiver, proprietary imaging software and an associated database for web based access and analysis.
For more information, visit www.check-cap.com and follow us on www://twitter.com/checkcap_.
Founder: Yoav Kimchy
CEO: Bill Densel
CTO: Yoav Kimchy
CFO: Lior Torem
X-ray Radar Device
Tweets by Check-Cap
47 articles with Check-Cap
IDE submission to the FDA for C-Scan® planned for the end of 2020; Initiation of a U.S. pivotal study planned for 2021.
Check-Cap Ltd. announced that it has entered into a definitive agreement with several existing institutional investors for the exercise of certain outstanding warrants to purchase up to an aggregate of 16,054,223 of its ordinary shares at a reduced exercise price of $0.60 per share.
Check-Cap Ltd . (the "Company" or "Check-Cap") (NASDAQ: CHEK), a clinical-stage medical diagnostics company advancing the development of C-Scan ® , the first and only preparation-free ingestible capsule for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that the Company received a let
Strengthened balance sheet through a total of $16.3 million in registered direct offerings and a private placement of ordinary shares in the first half of 2020
Check-Cap Ltd. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 5,000,000 of the Company's ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering.
Check-Cap Ltd. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,500,001 of the Company's ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering.
Check-Cap Ltd. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 6,666,669 of the Company's ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering.
Check-Cap Ltd. provided an update on the impact of the global COVID-19 coronavirus pandemic on the Company's operational and clinical activities.
1/2/2020Companies from across the globe announce updates to their business and pipeline.
Advancing towards IDE submission to the FDA, targeting initiation of U.S. pivotal study in late 2020
Successfully launched U.S. pilot study and reported positive final results from post-CE approval study of the C-Scan® System
Check-Cap Ltd. announced that Alex Ovadia, Chief Executive Officer, will provide a corporate overview at the Dawson James 5th Annual Small Cap Growth Conference, being held October 28-29, 2019 at the Wyndham Grand Hotel in Jupiter, Florida.
9/27/2019Biotech and pharma companies strengthen their leadership teams and boards of directors with this week's appointments.
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), announced today that Alex Ovadia, Chief Executive Officer, will provide a corporate overview at the H.C. Wainwright 21st Annual Global Investment Conference, being held September 8-10, 2019 in New York.
8/22/2019Companies from across the globe provide updates on their business and pipelines.
Check-Cap and GE Healthcare Announce Completion of Manufacturing Line Transfer Implementation and Qualification for the C-Scan® System Operated by GE Healthcare
GE Healthcare facility in Chicago to support clinical investigation needs of the C-Scan® System in the U.S.
7/11/2019Companies from across Europe, Asia and around the globe share pipeline and business updates.
Check-Cap Ltd., announced positive final results from its recently completed post-CE approval study evaluating the clinical performance and safety of the C-Scan system.
6/7/2019Pharma and biotech companies strengthen their executive and leadership teams with new appointments.
Mr. Belkar Brings More Than 20 Years of Global Medical Device Experience, Including at Medtronic and Mazor Robotics